One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
As an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
In patients undergoing percutaneous coronary intervention (PCI).
For use in patients with, or at risk for, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
Mechanism of Action: Bivalirudin directly inhibits thrombin, preventing its action on fibrinogen and its activation of platelets. This leads to a reduction in clot formation and platelet aggregation, providing anticoagulant effects.
Pharmacokinetics:
Absorption: Administered intravenously, it acts rapidly.
Distribution: Limited distribution, primarily in the bloodstream.
Metabolism: Cleaved by proteolytic enzymes.
Excretion: Renal excretion.
Form: Bivalirudin API is typically found as a white to off-white lyophilized powder.
Sixteen years of qualification
Audited Supplier
Pharma Sources Insight January 2025
